发明名称 Cyclic polypeptides for the treatment of heart failure
摘要 The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
申请公布号 US9266925(B2) 申请公布日期 2016.02.23
申请号 US201414336262 申请日期 2014.07.21
申请人 NOVARTIS AG 发明人 Zecri Frederic;Grosche Philipp;Yasoshima Kayo;Zhao Hongjuan;Yuan Jun;Usera Aimee Richardson;Lou Changgang;Kanter Aaron;Bruce Alexandra Marshall;Giumaraes Carla
分类号 C07K7/64;C07K16/46;A61K38/12;A61K45/06;C07K14/47 主分类号 C07K7/64
代理机构 代理人 Cross Sophie Binet
主权项 1. A cyclic polypeptide having the following formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I wherein: X1 is the N-terminus of the polypeptide and is either absent, Q, A or pE; X3 is P; X4 is selected from C, c, hC and D-hC; wherein the side chain of C, c, hC or D-hC forms a disulfide bond with the side chain of X7; X7 is C, c, hC or D-hC; and the side chain of X7 forms a disulfide bond with the side chain; X8 is K or F; X9 is G, A, a or absent; X10 is P or absent; X11 is D-Nle, Nle, M or f; and X12 is absent or P, f, a, D-Nva or D-Abu; X13 is the C-terminus and is absent or is selected from N-Methyl-L-phenylalanine F, f, a, y and Nal; wherein: Nle is L-norleucine; D-Nle is D-norleucine; D-hC is D-homocysteine hC is L-homocysteine; Nal is L-naphathaline; D-Nva is D-norvaline; D-Abu is D-2-aminobutyric acid; pE is L-pyroglutamic acid; or an amide, an ester or a salt of the polypeptide.
地址 Basel CH